

IVMB0218

Product Information

Product SKU: IVMB0218	Clone: MDX-010	Target: CTLA-4
Size: 500 µg		Isotype: Human IgG1k

Additional Information

Reactivity: Human	Host Species: Human
Antibody Type: Biosimilar Recombinant Human Monoclonal Antibody	Expression Host: HEK-293 Cells

Immunogen Information

Background: Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) is a protein receptor that serves as an immune checkpoint and down-regulates the immune system. CTLA-4 is constitutively expressed in regulatory T cells but is only upregulated in conventional T cells following activation. Many cancers, including Melanoma, are associated with CTLA-4 upregulation because the body's ability to recognize and destroy cancer cells is hampered by an inhibitory mechanism. Ipilimumab targets CTLA-4 and works by turning off this inhibitory mechanism and, thus, enhances the body's own immune response against cancer cells."² Emerging research suggests that combined blockade of PD-1 and CTLA-4, with Nivolumab and Ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.¹ This cost-effective, research-grade Anti-Human CTLA-4 (Ipilimumab) utilizes the same variable regions from the therapeutic antibody Ipilimumab making it ideal for research projects.

Endotoxin Level: < 1.0 EU/mg as determined by the LAL method

Applications: B

Synonyms: CD; GSE; GRD4; ALPS5; CD152; CTLA-4; IDDM12; CELIAC3

Antigen Distribution: CTLA4 is constitutively expressed in regulatory T cells.

Immunogen: Human CTLA-4

- Formulation:** This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
- Specificity:** This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Ipilimumab. Ipilimumab binds to Human CTLA-4. This product is for research use only.
- Product Preparation:** Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
- Storage & Handling:** Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.